taggbox - Eyenovia

Home
About
Technology
Pipeline
Partners
Investors
Careers
News + Resources
- News
- Resource Library
Menu Menu

Recent Posts

Eyenovia Reveals Positive Evidence that Optejet® Delivery Technology Decreased Inflammation from Preserved Glaucoma Solutions Compared to Drops January 13, 2023
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation December 13, 2022
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund November 29, 2022

Pipeline and Technology

MydCombi (Mydriasis)
MicroLine (Presbyopia)
MicroPine (Myopia)
Technology

Corporate Address

Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com

Copyright © 2022 Eyenovia, Inc. All rights reserved.

Twitter
Facebook
LinkedIn

Contact
Safe Harbor
Privacy Policy
Terms of Use